CSIMarket Company Name, Ticker, Competitors, else..
 
Pacific Biosciences Of California Inc   (NASDAQ: PACB)
Other Ticker:  
 
 
Price: $1.2200 $0.02 1.667%
Day's High: $1.26 Week Perf: -12.23 %
Day's Low: $ 1.20 30 Day Perf: -10.29 %
Volume (M): 8,627 52 Wk High: $ 4.10
Volume (M$): $ 10,525 52 Wk Avg: $1.87
Open: $1.24 52 Wk Low: $1.16



 Market Capitalization (Millions $) 333
 Shares Outstanding (Millions) 273
 Employees 796
 Revenues (TTM) (Millions $) 172
 Net Income (TTM) (Millions $) -394
 Cash Flow (TTM) (Millions $) -308
 Capital Exp. (TTM) (Millions $) 7

Pacific Biosciences Of California Inc
Pacific Biosciences of California Inc.
(also known as PacBio) is an American biotechnology company founded in 2004 by Stephen Turner and Jonas Korlach.
The company is headquartered in Menlo Park, California, and specializes in advanced DNA sequencing technology.
PacBio aims to revolutionize the field of genomics and personalize medicine through its innovative sequencing technology.
The company's flagship product is the PacBio Sequel System, which is a high-throughput DNA sequencing instrument that uses Single Molecule, Real-Time (SMRT) technology.
This technology allows for the real-time observation of DNA replication, leading to highly accurate and long-read sequencing results.
The system can detect various types of genomic variations, including non-coding DNA, structural variations, and epigenetic modifications.
PacBio's sequencing technology has numerous applications, including studies of genetic diseases, cancer research, microbiome analysis, and forensic analysis.
The company has collaborations with major academic institutions and research centers worldwide, such as the Wellcome Trust Sanger Institute, the Broad Institute, and the Max Planck Institute.
In 2020, PacBio merged with a special purpose acquisition company (SPAC) called Schr'dinger to go public.
The combined company trades on the Nasdaq under a new ticker symbol, "PACB.
" In summary, Pacific Biosciences Of California Inc is a biotech firm known for inventing and producing advanced DNA sequencing technology that allows for highly accurate and long-read sequencing results used for study of genetic diseases, cancer research, microbiome analysis and forensic analysis.
The company has collaborations with major academic institutions worldwide and went public in 2020 in collaboration with Schr'dinger through SPAC.


   Company Address: 1305 O?Brien Drive Menlo Park 94025 CA
   Company Phone Number: 521-8000   Stock Exchange / Ticker: NASDAQ PACB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
A   -0.59%    
AVTR   -5.67%    
BIO        2.7% 
ILMN   -0.43%    
RVTY   -5.35%    
TXG   -2.36%    
• View Complete Report
   



Pacific Biosciences Of California Inc

Pacific Biosciences Faces Revenue Setback: A 28.96% Decline Overshadows Strategic Innovations

Pacific Biosciences: A Mixed Fiscal Performance Amid Strategic InnovationsnMENLO PARK, Calif., Nov. 08, 2024n ? Pacific Biosciences of California Inc. (NASDAQ: PACB) reported a somewhat optimistic fiscal outlook despite facing challenges in revenue and market performance over the past year. The company has managed to decrease its loss per share to $-0.22, an improvement from $-0.26 a year ago, alongside a sequential improvement from $-0.64 per share in the previous reporting period. However, revenue has taken a significant hit, contracting by 28.96% year-over-year, from $54.90 million to $39.00 million, although it did see an 8.53% increase sequentially from $35.94 million.The revenue contraction is attributed to decreased sales across global markets, particularly in the Americas (-30.61%), Europe, Middle East and Africa (-17.05%), and Asia-Pacific (-31.67%), indicating broad challenges in demand for PacBio?s sequencing solutions. The company reported a net loss of $60.725 million, an improvement over the previous year?s loss of $66.869 million, highlighting a slight operational efficiency gain amid lower sales.
Product Service News

Advancing Genomic Horizons PacBios Innovations in Long-Read Sequencing

Published Thu, Nov 7 2024 3:35 AM UTC

In a significant stride towards democratizing genomic research, Pacific Biosciences (PacBio) has launched the Vega System, a new benchtop sequencing platform priced at $169,000. This development aims to make highly accurate long-read sequencing accessible to a wider array of laboratories. The Vega System utilizes HiFi sequencing technology, known for its precision, which is ...
Partnership

PacBio and Singapores National Precision Medicine Program Forge Pioneering Collaboration to Elevate Cancer G...

Published Fri, Oct 11 2024 1:05 PM UTC

In a groundbreaking alliance poised to redefine the landscape of cancer genomics, PacBio has joined forces with Singapore?s National Precision Medicine (NPM) program. This strategic partnership aims to harness the full potential of PacBio?s state-of-the-art HiFi sequencing technology, a sophisticated solution designed to deliver unparalleled insights into genetic diversity, ...
Product Service News

Unlocking Genomic Potential A New Era of Innovation Begins in Southeast Asia

Published Tue, Oct 1 2024 1:05 PM UTC

In a remarkable stride for the field of genomics, PacBio, A STAR, and Macrogen have collaborated to unveil a cutting-edge lab in Singapore, poised to revolutionize access to advanced genomic technologies in Southeast Asia. The initiative aims to leverage Pacific Biosciences? state-of-the-art HiFi sequencing technology, making highly accurate long-read sequencing and multi-om...
Shares

Strategic Compensation Moves and Groundbreaking Initiatives: PacBio Charts a Promising Course Amidst Shareholder Optimism

Published Fri, Sep 27 2024 8:05 PM UTC

Navigating New Frontiers: PacBio?s Inducement Grants and Their Implications for ShareholdersIn a pro-active endeavor to attract top-tier talent, Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leader in high-quality sequencing technology, has recently announced the granting of a non-qualified stock option covering 100,000 shares and restricted stock units (RSUs) fo...






Pacific Biosciences Of California Inc's Segments
Americas    51.55 % of total Revenue
Europe Middle East and Africa    23.38 % of total Revenue
Asia-Pacific    27.54 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com